Publications by authors named "R Shivakumar"
Background: Clinical manifestations of polycystic ovary syndrome (PCOS) are heterogeneous, with hallmarks including anovulation, androgen excess, and insulin resistance.
Case Report: A 38-year-old female with typical PCOS features presented with hypertension, obesity, and elevated fasting and postprandial insulin levels. She was enrolled in the Digital Twin (DT) platform, which uses artificial intelligence and Internet of Things to deliver personalized nutrition by predicting postprandial glucose responses and suggesting alternative foods with lower postprandial glucose response through a mobile app.
Background: This report is based on a 2023 nationwide survey and literature review of physician associates/assistants (PAs) in India. The National Commission for Allied and Healthcare Professions Act, 2021, which is being implemented in India, included guidelines for PA licensing, creating a unified national curriculum, and preventing malpractice.
Methods: Using a purposive sampling strategy, we surveyed 536 PAs in India between February 10 and April 30, 2023.
Article Synopsis
- Increased expression of VEGFR-2 in cancer cells leads to enhanced survival, growth, and proliferation of these cells.
- The study evaluates indazolyl-acyl hydrazones as potential antioxidant and anticancer agents, with some compounds showing significant inhibitory activity against free radicals.
- Compounds 4f and 4j demonstrated effective cell viability results in MCF-7 breast cancer cells and favorable binding to VEGFR-2, indicating their potential as therapeutic agents.
De Novo Design of Imidazopyridine-Tethered Pyrazolines That Target Phosphorylation of STAT3 in Human Breast Cancer Cells.
Bioengineering (Basel)
January 2023
In breast cancer (BC), STAT3 is hyperactivated. This study explored the design of imidazopyridine-tethered pyrazolines as a de novo drug strategy for inhibiting STAT3 phosphorylation in human BC cells. This involved the synthesis and characterization of two series of compounds namely, 1-(3-(2,6-dimethylimidazo [1,2-a]pyridin-3-yl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-(4-(substituted)piperazin-1-yl)ethanone and N-substituted-3-(2,6-dimethylimidazo[1,2-a]pyridin-3-yl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazoline-1-carbothioamides.
View Article and Find Full Text PDFA real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
Mult Scler Relat Disord
October 2022
Background: Natalizumab (NTZ) is increasingly being used in Indian multiple sclerosis (MS) patients. There are no reports on its safety and efficacy, especially with respect to the occurrence of progressive multifocal leukoencephalopathy (PML).
Objectives: To describe the patient characteristics, treatment outcomes, and adverse events, especially the occurrence of PML in NTZ-treated patients.